Volume 90 Issue 21 | pp. 34-35
Issue Date: May 21, 2012

Bosutinib Buyer Beware

The wrong isomer has been sold under the name of the cancer-fighting compound
Department: Science & Technology
News Channels: Biological SCENE
Keywords: bosutinib, SKI-606, kinase inhibitor

Some bad bosutinib is going around. Scientists who have purchased the compound may actually have received an isomer rather than the genuine molecule.

Bosutinib, also known as SKI-606, is currently in Phase III clinical trials to treat chronic myeloid leukemia. Officials at Pfizer, the company sponsoring the clinical trials, say that only genuine bosutinib has been administered to patients. However, as a selective kinase inhibitor, the compound is also used in medical and . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society